Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles

Parasitic diseases such as malaria, leishmaniasis, and trypanosomiasis represent a significant global burden and pose a great challenge to drug discovery and delivery scientists due to their intracellular nature and disseminated locations. Moreover, poor rate of discovery in the anti-parasitic segme...

Full description

Saved in:
Bibliographic Details
Published in:Advanced drug delivery reviews 2007-07, Vol.59 (6), p.505-521
Main Authors: Date, Abhijit A., Joshi, Medha D., Patravale, Vandana B.
Format: Article
Language:English
Subjects:
Animals
Antiparasitic Agents - administration & dosage
Antiparasitic Agents - therapeutic use
Colloids
Drug Delivery Systems
Humans
Leishmaniasis
Lipids - administration & dosage
Lipids - therapeutic use
Liposomes
Liposomes - therapeutic use
Malaria
Nanoparticles
Nanoparticles - therapeutic use
Nanostructured lipid carriers (NLCs)
Parasitic diseases
Parasitic Diseases - drug therapy
Polymers - administration & dosage
Polymers - therapeutic use
Solid lipid nanoparticles (SLNs)
Trypanosomiasis
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Parasitic diseases such as malaria, leishmaniasis, and trypanosomiasis represent a significant global burden and pose a great challenge to drug discovery and delivery scientists due to their intracellular nature and disseminated locations. Moreover, poor rate of discovery in the anti-parasitic segment seen in last few decades has necessitated effective management of existing drugs by modulating their delivery. The review focuses on the biological and biopharmaceutical issues to be considered in the design of delivery strategy for treating parasitic infections such as malaria, leishmaniasis, and trypanosomiasis. Also, it describes the role of the colloidal carriers liposomes, polymeric nanoparticles, lipid nanoparticles including lipid drug conjugate (LDC) nanoparticles in optimizing the delivery of anti-malarial, anti-leishmanial and anti-trypanosomial agents. Furthermore, the review emphasizes especially the potential of solid lipid nanoparticles (SLN) in the treatment of parasitic infections with the help of recent reports and our own experience.
ISSN:0169-409X
1872-8294
DOI:10.1016/j.addr.2007.04.009